Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study

2016-04-17 17:16:08 | BioPortfolio


This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with Atypical Alzheimer's Disease and how burden may change over a two-year period.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Atypical Alzheimer's Disease


F-18 AV 1451, C-11 PiB


Not yet recruiting


Mayo Clinic

Results (where available)

View Results


Published on BioPortfolio: 2016-04-17T17:16:08-0400

Clinical Trials [1266 Associated Clinical Trials listed on BioPortfolio]

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

This study will evaluate longitudinal change of tau deposition as measured by 18F-AV-1451 uptake over time.

18F-AV-1451 Autopsy Study

This study is designed to test the relationship between ante-mortem 18F-AV-1451 Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's dis...

Clinical Evaluation of 18F-AV-1451

This study is designed to expand the database of 18F-AV-1451 safety and tau binding as measured by PET imaging and to provide standardized conditions for 18F-AV-1451 use, data collection a...

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects

This is a cross-sectional and longitudinal study that will evaluate imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, mild cognitive impairment (MCI) and Alzheimer'...

18F-AV-1451 High Resolution Autopsy Study

The study is designed to examine the relationship between imaging results detected on a 18F-AV-1451 PET scan and pathology found at autopsy within six months of imaging.

PubMed Articles [15742 Associated PubMed Articles listed on BioPortfolio]

Assessment of APOE in atypical parkinsonism syndromes.

Atypical parkinsonism syndromes are a heterogeneous group of neurodegenerative disorders that include corticobasal degeneration (CBD), Lewy body dementia (LBD), multiple system atrophy (MSA), and prog...

Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease.

The aims of this study were: to examine regional rates of change in tau-PET uptake and grey matter volume in atypical Alzheimer's disease (AD); to investigate the role of age in such changes; to descr...

rs242557 variant is associated with hippocampus tau uptake on F-AV-1451 PET in non-demented elders.

The microtubule-associated protein tau gene () rs242557 variant is associated with multiple tauopathies and dementia. This study investigated whether it was correlated with brain tau-PET uptake in non...

Identify compounds's target against Alzheimer's disease based on silico approach.

Alzheimer's disease swept every corner of the globe and the number of patients worldwide has been rising. At present, there are as many as 30 million people with Alzheimer's disease in the world, and ...

F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy.

Posterior cortical atrophy and dementia with Lewy bodies are 2 distinct clinical syndromes, yet they can overlap in symptoms and occipital hypometabolism. Patients with dementia with Lewy bodies often...

Medical and Biotech [MESH] Definitions

The period of history from 1451 through 1600 of the common era.

Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.

Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.

A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

More From BioPortfolio on "Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study"

Quick Search

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Searches Linking to this Trial